Key Takeaway: Precision BioSciences announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society. The presentation will showcase long-term preclinical efficacy and durability data for PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy. The company is on track to file an IND and/or CTA by the end of 2025, with clinical data expected in 2026.
Price reaction · baseline $5.09 (2025-09-29 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+8.4%
day 1
+6.9%
day 3
+6.9%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation of long-term preclinical efficacy data.
Support for PBGENE-DMD in treating Duchenne Muscular Dystrophy.
On track for IND/CTA filing by end of 2025.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy – – On track to file an IND and/or CTA by the end of 2025; clinical data anticipated in 2026- DURHAM, N.C. –(BUSINESS WIRE)–Sep.
Frequently Asked Questions
What is PBGENE-DMD?
PBGENE-DMD is a treatment being developed for Duchenne Muscular Dystrophy.
When is the IND filing expected?
The IND and/or CTA filing is expected by the end of 2025.
What data will be presented at the Congress?
The presentation will highlight long-term preclinical efficacy and durability data.
When is clinical data anticipated?
Clinical data for PBGENE-DMD is anticipated in 2026.